Mirum Pharmaceuticals, Inc. (MIRM) Raises 2026 Sales Guidance to $715M-$720M

What happened

Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $715M-$720M. The release does not provide the prior guidance figure, so the size of the increase cannot be measured from the supplied text.

Confirmed

Global impact / market context

A higher sales target tells investors management expects more revenue from its approved drugs, which can support profit and cash available for research and pipeline work. Without the prior figure, the increase's size and credibility cannot be judged.

Analyst inference

Mirum is described as a mid-cycle commercial company with approved products and a pipeline moving through clinical and regulatory milestones, which means development stages and approval steps. Upcoming approvals and label expansions, meaning broader approved uses, are framed as the next catalysts.

Analyst inference

What to watch

1. Watch whether Mirum delivers net product sales within the raised $715M-$720M range for full-year 2026, since the release gives no prior guidance figure for comparison. Confirmed
2. Watch progress on the stated upcoming approvals and label expansions, because broader approved uses could add revenue, while delays could slow sales growth and cash available. Analyst inference
3. Watch for future company disclosures that give the prior guidance figure or update the 2026 sales range, which would let investors measure the size of this increase. Proposed

Evidence

• Original source link unavailable